Blood and serum substances for markers of prostate cancer

Microscopy Research and Technique

Volumn 51, Issue 5, 2000, Pages 430-435

  Bangma, Chris H ^a   Verhagen, Paul C M S ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

PCR; Prostate malignancies; PSA; Serummarkers

Indexed keywords

BLOOD; DISEASE CONTROL; UROLOGY;

'CURRENT; BENIGN DISEASE; MALIGNANT DISEASE; PCR; PRE-TREATMENTS; PROSTATE CANCERS; PROSTATE CARCINOMA; PROSTATE MALIGNANCY; PSA; SERUMMARKER;

DISEASES;

CELL ANTIGEN; KALLIKREIN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER RESEARCH; EARLY DIAGNOSIS; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR DIFFERENTIATION;

EID: 0034564176     PISSN: 1059910X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0029(20001201)51:5<430::AID-JEMT5>3.0.CO;2-1     Document Type: Article

References (16)

1. Bangma CH, Kranse R, et al. 1997. The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma. J Urol 157: 544-547.
2. Becker C, Piironen T, et al. 2000. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum (in process citation). J Urol 163:311-316.
3. Beckett ML, Cazares LH, et al. 1999. Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer [In Process Citation]. Clin Cancer Res 5:4034-4040.
4. Brawer MK, Meyer GE, et al. 1998. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 52:372-378.
5. Coffey DS. 1993. Prostate cancer. An overview of an increasing dilemma. Cancer 71 (Suppl 3):880-886.
6. de la Taille A, Olsson CA, et al. 1999. Blood-based reverse transcriptase polymerase chain reaction assays for prostatic specific antigen: long term follow-up confirms the potential utility of this assay in identifying patients more likely to have biochemical recurrence (rising PSA) following radical prostatectomy. Int J Cancer 84:360-364.
7. Fidler IJ. 1970. Metastasis: guantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2′-deoxyuridine. J Natl Cancer Inst 45:773-782.
8. Lilja H, Piironen TP, Rittenhouse HG, Mikolajczyk SD, Slawin KM. 2000. Overview: prostate specific antigen. In: Genitourinary oncology. Philadelphia.
9. Moreno JG, Croce CM, et al. 1992. Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res 52:6110-6112.
10. Polascik TJ, Oesterling JE, et al. 1999. Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J Urol 162:293-306.
11. Reiter RE, Gu Z, et al. 1998. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A 95:1735-1740.
12. Rietbergen JB, Hoedemaeker RF, et al. 1999. The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study. J Urol 161:1192-1198.
13. Schroder FH, Bangma CH. 1997. The European Randomized Study of Screening for Prostate Cancer (ERSPC). Br J Urol 79(Suppl 1):68-71.
14. Van Cangh PJ, De Nayer P, et al. 1996. Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA. Urology 48(Suppl 6A):67-70.
15. Wang X, Brannigan RE, et al. 1997. One core positive prostate biopsy is a poor predictor of cancer volume in the radical prostatectomy specimen. J Urol 158:1431-1435.
16. Ylikoski A, Sjoroos M, et al. 1999. Quantitative reverse transcription-PCR assay with an internal standard for the detection of prostate-specific antigen mRNA. Clin Chem 45:1397-1407.